The calcineurin inhibitor, FK506, does not alter glutamate transport in the ischaemic mouse retina

David J. Holcombe, Glen A. Gole, Nigel L. Barnett

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The protein phosphatase 2B inhibitor, FK506, is an immunomodulatory polypeptide that has neuroprotective properties, the mechanisms of which have not been elucidated. A possible mechanism may be phosphorylation-mediated regulation of glutamate transporter activity. In the present study, we investigated the effect of FK506 on glutamate transporter localization and activity in the ischaemic mouse retina. FK506 did not appear to modulate the localization or activity of glutamate transporters under simulated ischaemic conditions. Our present data suggest that the mechanism by which FK506 exerts its neuroprotective action is not attributable to alterations in retinal glutamate transport.

Original languageEnglish
Pages (from-to)315-319
Number of pages5
JournalExperimental Eye Research
Volume91
Issue number2
DOIs
Publication statusPublished - 1 Aug 2010
Externally publishedYes

Fingerprint

Tacrolimus
Amino Acid Transport System X-AG
Retina
Glutamic Acid
Phosphorylation
Peptides
Calcineurin Inhibitors

Cite this

@article{c29d534cd58744828bee02ccd27c65fb,
title = "The calcineurin inhibitor, FK506, does not alter glutamate transport in the ischaemic mouse retina",
abstract = "The protein phosphatase 2B inhibitor, FK506, is an immunomodulatory polypeptide that has neuroprotective properties, the mechanisms of which have not been elucidated. A possible mechanism may be phosphorylation-mediated regulation of glutamate transporter activity. In the present study, we investigated the effect of FK506 on glutamate transporter localization and activity in the ischaemic mouse retina. FK506 did not appear to modulate the localization or activity of glutamate transporters under simulated ischaemic conditions. Our present data suggest that the mechanism by which FK506 exerts its neuroprotective action is not attributable to alterations in retinal glutamate transport.",
author = "Holcombe, {David J.} and Gole, {Glen A.} and Barnett, {Nigel L.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1016/j.exer.2010.04.011",
language = "English",
volume = "91",
pages = "315--319",
journal = "Experimental Eye Research",
issn = "0014-4835",
publisher = "Academic Press Inc.",
number = "2",

}

The calcineurin inhibitor, FK506, does not alter glutamate transport in the ischaemic mouse retina. / Holcombe, David J.; Gole, Glen A.; Barnett, Nigel L.

In: Experimental Eye Research, Vol. 91, No. 2, 01.08.2010, p. 315-319.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The calcineurin inhibitor, FK506, does not alter glutamate transport in the ischaemic mouse retina

AU - Holcombe, David J.

AU - Gole, Glen A.

AU - Barnett, Nigel L.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - The protein phosphatase 2B inhibitor, FK506, is an immunomodulatory polypeptide that has neuroprotective properties, the mechanisms of which have not been elucidated. A possible mechanism may be phosphorylation-mediated regulation of glutamate transporter activity. In the present study, we investigated the effect of FK506 on glutamate transporter localization and activity in the ischaemic mouse retina. FK506 did not appear to modulate the localization or activity of glutamate transporters under simulated ischaemic conditions. Our present data suggest that the mechanism by which FK506 exerts its neuroprotective action is not attributable to alterations in retinal glutamate transport.

AB - The protein phosphatase 2B inhibitor, FK506, is an immunomodulatory polypeptide that has neuroprotective properties, the mechanisms of which have not been elucidated. A possible mechanism may be phosphorylation-mediated regulation of glutamate transporter activity. In the present study, we investigated the effect of FK506 on glutamate transporter localization and activity in the ischaemic mouse retina. FK506 did not appear to modulate the localization or activity of glutamate transporters under simulated ischaemic conditions. Our present data suggest that the mechanism by which FK506 exerts its neuroprotective action is not attributable to alterations in retinal glutamate transport.

UR - http://www.scopus.com/inward/record.url?scp=77954954241&partnerID=8YFLogxK

U2 - 10.1016/j.exer.2010.04.011

DO - 10.1016/j.exer.2010.04.011

M3 - Article

VL - 91

SP - 315

EP - 319

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

IS - 2

ER -